

Resource Summary Report

Generated by [RRID](#) on Aug 9, 2026

CD159c (NKG2C)-APC, human

RRID:AB_2655396

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-103-636, RRID:AB_2655396

Antibody Information

URL: http://antibodyregistry.org/AB_2655396

Proper Citation: Miltenyi Biotec Cat# 130-103-636, RRID:AB_2655396

Target Antigen: CD159c (NKG2C)

Host Organism: human

Clonality: monoclonal

Comments: Discontinued: 8-2018; Target Distribution NK cells; target type CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:
Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-117-398. (RRID:AB_2727933).

Antibody Name: CD159c (NKG2C)-APC, human

Description: This monoclonal targets CD159c (NKG2C)

Target Organism: human

Clone ID: REA205

Antibody ID: AB_2655396

Vendor: Miltenyi Biotec

Catalog Number: 130-103-636

Record Creation Time: 20250819T205235+0000

Record Last Update: 20250819T210642+0000

Ratings and Alerts

No rating or validation information has been found for CD159c (NKG2C)-APC, human.

Warning: Discontinued: 2021

Discontinued: 8-2018; Target Distribution NK cells; target type CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-117-398. (RRID:AB_2727933).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Cazzetta V, et al. (2021) NKG2A expression identifies a subset of human V α 2 T cells exerting the highest antitumor effector functions. Cell reports, 37(3), 109871.

Good CR, et al. (2021) An NK-like CAR T cell transition in CAR T cell dysfunction. Cell, 184(25), 6081.